NASDAQ:SPRY | Free Cash Flow | ARS Pharmaceuticals, Inc.

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2020-03-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31-$44.95M$0.00-$44.95M
2025-12-31-$43.49M$0.00-$43.49M
2025-03-31-$40.74M$91,000.00-$40.83M
2024-12-31$42M$302,000.00$41.7M83.51%
2024-03-31-$6.71M$83,000.00-$6.79M
2023-12-31-$17.41M-$91,000.00-$17.5M
2023-03-31-$12.43M$193,000.00-$12.62M
2022-12-31-$20.5M$126,000.00-$20.62M
2022-03-31-$6.93M$21,000.00-$6.95M
2021-12-31$27.89M-$767,000.00$27.13M59.26%
2021-03-31-$12.2M$35,000.00-$12.24M
2020-12-31-$11.1M$247,000.00-$11.34M
2020-03-31-$7.63M$33,000.00-$7.66M

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31-$170.87M$339,000.00-$171.21M
2024-12-31$13.55M$563,000.00$12.99M162.35%
2023-12-31-$59.27M$175,000.00-$59.44M
2022-12-31-$40.08M$199,000.00-$40.28M
2021-12-31-$17.56M$55,000.00-$17.62M
2020-12-31-$31.2M$917,000.00-$32.11M

Research interface only. Not investment advice. Prices are a checked-in snapshot, not live quotes.